UTHR buyback activity: $1.50B repurchased in Q1 (6.35% of market cap)美国联合医疗公司（UTHR）Q1 回购 $1.50B，约占市值 6.35%

Reported Repurchase Activity

United Therapeutics Corporation (UTHR) reported $1.50 billion in common stock repurchase cash outflows in Q1 2026, with the period ending March 31, 2026; the repurchase size equals 6.35% of the company’s current $23.64 billion market capitalization. This is a completed, period-end repurchase recorded in the quarterly cash flow statement, not a newly announced repurchase authorization, with no associated authorization update filings disclosed in public records.

Capital Allocation Signal

The company paid $0 in common stock dividends during Q1 2026, with operating cash flow of $463.3 million and free cash flow of $362.5 million for the period. The $1.50 billion single-quarter repurchase outlay far exceeds the quarter’s free cash flow, indicating the company drew on accumulated cash reserves to execute the buyback rather than relying solely on cash generated from current operating activities.

Shareholder Return Context

For a large-cap biotech firm with a $23.64 billion market cap, a single-quarter repurchase equal to 6.35% of total market value is significantly above typical levels. Most peer large-cap biotechs typically conduct quarterly repurchases ranging from 1% to 3% of their market capitalization, making this a notably aggressive capital allocation move that signals management’s assessment of current share pricing.

Limitations of the Signal

This completed repurchase does not confirm that future repurchase activity will match this pace, nor does it directly prove the company’s stock is undervalued or that it will provide near-term stock price support. Separately, CFO James Edgemond disclosed multiple insider transactions on May 29, 2026, via Form 4 filings, including M-exempt share holdings and open market stock sales; these trades have no direct link to the Q1 2026 repurchase activity and should be evaluated independently.